ASH 2023 | The ALLG CML13 ASCEND-CML study: high major molecular responses with asciminib treatment for CP-CML

Timothy Hughes • 9 Dec 2023

ASH 2023

Timothy Hughes, MD, MBBS, FRACP, FRCPA, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, presents promising long-term outcomes from the Australasian Leukaemia and Lymphoma Group (ALLG) CML13 ASCEND-CML trial, evaluating asciminib, an allosteric inhibitor of BCR::ABL1, in the frontline treatment of chronic myeloid leukemia in the chronic phase (CP-CML). After a median follow-up of 23 months, robust major molecular responses (MMR) were observed, with low rates of transformation and adverse events (AEs). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.